Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2732740 | 0.98 | CRBN (0.55) | CRBNCYP19A1TBXAS1 | |
| SCHEMBL278215 | 0.90 | CRBN (0.50) | CRBNCYP19A1TBXAS1 | |
| SCHEMBL277992 | 0.88 | CRBN (0.48) | CRBNCYP19A1TBXAS1 | |
| SCHEMBL278221 | 0.88 | CRBN (0.48) | CRBNCYP19A1TBXAS1 | |
| SCHEMBL9576585 | 0.88 | CRBN (0.48) | CRBNCYP19A1TBXAS1 | |
| SCHEMBL5435030 | 0.88 | CRBN (0.48) | CRBNCYP19A1TBXAS1 | |
| SCHEMBL277887 | 0.88 | CRBN (0.48) | CRBNCYP19A1TBXAS1 | |
| SCHEMBL278367 | 0.85 | CRBN (0.50) | CRBNCYP19A1TBXAS1 | |
| SCHEMBL22018269 | 0.81 | CRBN (0.77) | CRBN | |
| SCHEMBL19586017 | 0.80 | CRBN (0.44) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| CN-111757900-B | Method for reducing aldehyde emissions in polyurethane-containing materials | 亨茨曼国际有限公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3728368-A1 | METHOD FOR REDUCTION OF ALDEHYDE EMISSION IN POLYURETHANE COMPRISING MATERIALS | Huntsman International LLC (US) | 2020-10-28 | — | — | EP | disclosed |
| CN-111757900-A | Method for reducing aldehyde emissions in polyurethane-containing materials | 亨茨曼国际有限公司 | 2020-10-09 | — | — | CN | disclosed |
| CN-104159942-B | Comprise the curable compositions of polyisocyantates composition | 亨茨曼国际有限公司 | 2016-10-12 | — | — | CN | disclosed |
| EP-2830761-A1 | POLYISOCYANATE TRIMERIZATION CATALYST COMPOSITION | Huntsman International LLC (US) | 2015-02-04 | — | — | EP | disclosed |
| CN-104159942-A | Curable composition comprising a polyisocyanate composition | HUNTSMAN INT LLC | 2014-11-19 | — | — | CN | disclosed |
| EP-2797974-A1 | CURABLE COMPOSITION COMPRISING A POLYISOCYANATE COMPOSITION | Huntsman International LLC (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013143841-A1 | POLYISOCYANATE TRIMERIZATION CATALYST COMPOSITION | HUNTSMAN INTERNATIONAL LLC (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013098034-A1 | CURABLE COMPOSITION COMPRISING A POLYISOCYANATE COMPOSITION | HUNTSMAN INTERNATIONAL LLC (US) | 2013-07-04 | — | — | WO | disclosed |
| US-7192967-B1 | Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents | ASTELLAS PHARMA GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1730142-A1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050222047-A1 | Novel ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION | 2005-10-06 | — | — | US | disclosed |
| WO-2005085242-A1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-6506764-B1 | B-X-(CH2)m-CR1R2-(CH2)n-CO-Y (I) have therapeutic utility as inhibitors of metalloproteinases etc. for medicine by human articular cartilage cells and also involved in the destruction of myelin basic protein, a phenomenon associated with | DARWIN DISCOVERY, LTD. (GB) | 2003-01-14 | — | — | US | disclosed |
| EP-1177174-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000069822-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
| US-4956368-A | Antipsychotic agents | BRISTOL-MYERS COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222047-A1 | Novel ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | PREP, P4HB, P4HA1 | CRBN 645/4885CYP19A1 340/4885TBXAS1 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.